HIV Infections
Conditions
Keywords
treatment experienced
Brief summary
The purpose of this study is to describe the Central Nervous System exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state.
Detailed description
15 HIV-1 infected subjects currently receiving stable antiretroviral therapy will be recruited. At study entry, within 14 days of screening procedures, subjects will commence maraviroc dosed at 150 mg twice daily. For the rest of study period antiretroviral therapy will comprise: * Truvada™ one tablet once daily at 0900 * Kaletra™ two tablets twice daily 0900 and 2100 * maraviroc 150 mg twice daily at 0900 and 2100 Subjects will attend for regular clinic visits during study treatment phase. On day 15, subjects will attend the unit in the morning prior to usual dosing time. Blood with be drawn to assess plasma maraviroc concentration pre dose and pre lumbar puncture. A lumbar puncture will be performed under standard aseptic techniques to asses CSF maraviroc concentration and routine CSF parameters. On completion of this study visit, subjects will cease maraviroc, continue on their usual antiretroviral regimen and attend for a follow up visit 10 days later.
Interventions
DRUGMaraviroc
150mg twice daily
Sponsors
Pfizer
Imperial College London
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* HIV-1 infected males or females * signed informed consent * plasma HIV RNA \< 50 copies/mL at screening and on at least one other occasion over the last 3 months * currently receiving a stable antiretroviral regimen comprising of: * tenofovir 245 mg daily * emtricitabine 200 mg daily * a boosted protease inhibitor * no previous protease inhibitor resistance documented on HIV-1 genotypic resistance testing * Between 18 to 65 years of age, inclusive * subjects in good health upon medical history, physical exam, and laboratory testing * Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study including 30 days following last dose of study drug: * barrier contraceptives (condom, diaphragm with spermicide) * IUD PLUS a barrier contraceptive * Female subjects of childbearing potential must have a negative pregnancy test. * Male subjects who are heterosexually active must use two forms of barrier contraception (e.g., condom with spermicide) during heterosexual intercourse, from screening through completion of the study including 30 days following last dose of study drug. * Have no serologic evidence of active HBV infection evidenced by negative hepatitis B surface antigen and no serologic evidence of hepatitis C virus infection by a HCV antibody or HCV PCR. * Have screening laboratory results (haematology, chemistry, and urinalysis) that fall within the normal range of the central laboratory's reference ranges unless the results have been determined by the Investigator to have no clinical significance
Exclusion criteria
* current alcohol abuse or drug dependence * active opportunistic infection or significant co-morbidities including dementia * current prohibited concomitant medication (as listed in section 4.1.4) * Have a body mass index (BMI) \> 32 * Contraindication to lumbar puncture examination. Such as: * Existing neurological diseases * Bleeding disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) | 15 days | To describe the CNS exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state. It were assessed by in vivo cerebral (1)H magnetic resonance spectroscopy ((1)H-MRS). Cerebral MRS imaging (T1- and T2-weighted images) was performed on a Phillips Achieva™ 1.5 Tesla magnetic resonance (MR) scanner (Phillips NV, Best, Netherlands) and studied by an experienced neuroradiologist |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Adverse Events | 15 days | To evaluate the short term safety and tolerability of maraviroc in HIV-1 infected subjects on stable antiretroviral therapy |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Maraviroc Maraviroc: 150mg twice daily | 12 |
| Total | 12 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Physician Decision | 1 |
Baseline characteristics
| Characteristic | Maraviroc |
|---|---|
| Age, Continuous | 42 years STANDARD_DEVIATION 7.9 |
| Baseline CD4 cell count | 503 cells/ul STANDARD_DEVIATION 199 |
| BMI | 28 kg/m^2 STANDARD_DEVIATION 3.5 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 7 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 4 Participants |
| Region of Enrollment United Kingdom | 12 participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 9 Participants |
| Years since HIV diagnosis | 11 years STANDARD_DEVIATION 4.6 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 12 |
| other Total, other adverse events | 0 / 12 |
| serious Total, serious adverse events | 0 / 12 |
Outcome results
Primary
CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS)
To describe the CNS exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state. It were assessed by in vivo cerebral (1)H magnetic resonance spectroscopy ((1)H-MRS). Cerebral MRS imaging (T1- and T2-weighted images) was performed on a Phillips Achieva™ 1.5 Tesla magnetic resonance (MR) scanner (Phillips NV, Best, Netherlands) and studied by an experienced neuroradiologist
Time frame: 15 days
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Maraviroc | CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) | 1.01 ratio |
Secondary
Number of Participants With Adverse Events
To evaluate the short term safety and tolerability of maraviroc in HIV-1 infected subjects on stable antiretroviral therapy
Time frame: 15 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Maraviroc | Number of Participants With Adverse Events | 0 Participants |